Zopiclone 7.5 EU is a potent sedative-hypnotic medication that belongs to the class of drugs called cyclopyrrolones. It is primarily used for the short-term treatment of insomnia, characterized by difficulty falling asleep, staying asleep, or waking up too early. Zopiclone 7.5 EU is formulated to promote sleep by reducing the time taken to fall asleep, prolonging the duration of sleep, and improving the overall quality of sleep.
The active ingredient in Zopiclone 7.5 EU is zopiclone, a synthetic compound that acts on the brain’s GABA-A receptors, which are responsible for inhibiting the central nervous system’s activity. Zopiclone enhances the activity of GABA, leading to sedation, muscle relaxation, and anxiolysis. It does not affect the rapid eye movement (REM) stage of sleep, which is responsible for dreaming, but it reduces the time spent in the non-REM stages, which are associated with restorative functions.
Zopiclone 7.5 EU is available in the form of tablets that are taken orally. The tablets are oblong-shaped, white, and film-coated, with “Z7.5” imprinted on one side and a break line on the other side. Each tablet contains 7.5 mg of zopiclone as the active ingredient, as well as other inactive ingredients such as lactose monohydrate, maize starch, colloidal anhydrous silica, magnesium stearate, hypromellose, macrogol 400, and titanium dioxide.
Zopiclone 7.5 EU should be taken shortly before bedtime, and the recommended dose is one tablet per day. The dose may be adjusted based on individual response and tolerance, but it should not exceed 7.5 mg per day. The tablet should be swallowed whole with water, without crushing, chewing, or breaking it. Zopiclone 7.5 EU should not be taken with alcohol or other sedative medications, as it can increase the risk of adverse effects, including respiratory depression, coma, or death.
Zopiclone 7.5 EU is contraindicated in patients who have a history of hypersensitivity to zopiclone or any of the inactive ingredients in the tablet. It should also be avoided in patients with severe respiratory insufficiency, sleep apnea syndrome, myasthenia gravis, or severe hepatic impairment. Zopiclone 7.5 EU should be used with caution in elderly patients, patients with renal impairment, and patients with a history of drug or alcohol abuse.
The most common adverse effects associated with Zopiclone 7.5 EU are drowsiness, dizziness, dry mouth, and headache. These effects are usually mild to moderate and resolve spontaneously within a few days of treatment initiation. Other less common but more serious adverse effects include paradoxical reactions, such as agitation, confusion, hallucinations, and nightmares, as well as respiratory depression, hypotension, and angioedema.
In conclusion, Zopiclone 7.5 EU is a potent sedative-hypnotic medication that is used for the short-term treatment of insomnia. It is formulated to promote sleep by reducing the time taken to fall asleep, prolonging the duration of sleep, and improving the overall quality of sleep. Zopiclone 7.5 EU should be taken shortly before bedtime, and the recommended dose is one tablet per day. It should be used with caution in certain patient populations, and patients should be advised to avoid alcohol and other sedative medications while taking Zopiclone 7.5 EU.